After hours: January 29 at 6:19:11 PM EST Loading Chart for CRVS ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

OBIO Orchestra BioMed Holdings, Inc.